A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
← catalyst calendarNCT07037862 · readout in 952 d
Sponsored by Entrada Therapeutics, Inc. (industry) · TRDA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
24estimated
Sites
14
Countries
Belgium, Italy, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2029-03-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy (DMD)
Interventions
- Drug: ENTR-601-44
- Drug: ENTR-601-44 - matching placebo
Primary outcome
what the primary-completion date above is the date OFNumber of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and Open Label (OL) Period)
measured From baseline through End of Study (up to 62 weeks).
Permalink · TRDA's whole pipeline · Catalyst calendar · Every registered study · What changed